New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For ACT;TEVA;ENDP;COV;ABT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | all recent news | >>
October 1, 2014
07:45 EDTCOVMedtronic has upside in multiple scenarios, says BofA/Merrill
Subscribe for More Information
07:30 EDTACTSalix price target raised to $185 from $155 at Stifel
Subscribe for More Information
September 30, 2014
17:11 EDTENDPEndo reaches master settlement agreements to resolve remaining AMS claims
Subscribe for More Information
September 29, 2014
08:55 EDTACTCelgene price target raised to $115 from $100 at RBC Capital
RBC Capital increased its price target on Celgene (CELG) as the firm now estimates that the company's new oral Crohn's disease drug GED-0301 will generate $1B in sales. The firm expects Celgene's stock to rise further as it predicts that Phase II data for the company's Crohn's treatment will be much better than the data for AbbVie's (ABBV) Crohn's treatment, Humira. RBC predicts that Celgene's long-term 2020 guidance will beat expectations if the company is able to reach a legal settlement with Actavis (ACT.). RBC Capital keeps an Outperform rating on Celgene.
08:32 EDTACTSalix has 55% chance of being acquired, says Sterne Agee
Subscribe for More Information
07:19 EDTTEVAUBS to hold a field trip
Subscribe for More Information
06:58 EDTCOVU.S. tax regulations may require Medtronic-Covidien renegotiations, Reuters says
Subscribe for More Information
06:22 EDTACTAllergan, Actavis deal may become increasingly likely, says Citigroup
Citigroup believes a merger between Allergan (AGN) and Actavis (ACT) will become increasingly likely if Allergan is unable to consummate an acquisition in the near-term. Citi views Salix (SLXP) as a better strategic fit for Actavis. It estimates that at a $180 per share takeover price, a Salix acquisition would be value enhancing to Actavis and "roughly value neutral" to Allergan. The firm believes Allergan is "stock between a rock and a hard place regarding potential M&A" as it seeks to fend off a hostile takeover from Valeant (VRX).
05:26 EDTTEVAProtalix appoints Moshe Manor as CEO
Subscribe for More Information
September 28, 2014
16:21 EDTACTAllergan holder Jackson Square Partners against large acquisition
Jeff Van Harte, chairman and chief investment officer of Allergan (AGN) investor Jackson Square Partners, sent a letter to Allergan's board which said in part: "We have owned Allergan equity for well over a decade. Our clients' portfolios hold over $1B of the company's stock. As their fiduciary, we feel obligated to publicly raise our concerns regarding the value-creation strategy the Board of Directors appears to be pursuing. You have refused to engage with Valeant (VRX), describing their takeover offer as "grossly inadequate."... Press reports indicate Allergan has recently been approached by a second bidder, Actavis (ACT). Though the company has not commented, we assume you have declined to engage with them as well. Instead, the Board seems focused on hastily closing a large acquisition. Given the circumstances, this can only mean that the price paid must be dramatically higher than would otherwise be the case, depressing potential returns on invested capital. More disturbingly, this approach appears to be intended to not only preempt shareholder approval, but also eliminate interest from the various bidders for the company. Management has defended this stance by claiming that shareholder feedback has been strongly in favor of an acquisition, preferably to be completed prior to the special meeting on December 18.That a large majority of Allergan shareholders would support such a strategy is hard to fathom, and doesn't reflect our understanding of the situation. If there are investors who feel this way, however, we want to be very clear: we are not among them. Completing an acquisition prior to the special meeting will all but eliminate Allergan's alternatives for creating value. Limiting options is not in shareholders' interests. We strongly urge you to fully engage all available paths, thereby ensuring value maximization. Please forward this letter to the rest of the Board." Note that Allergan has been reported to be in talks to buy Salix Pharmaceuticals (SLXP).
September 26, 2014
16:55 EDTCOVMarket ends week lower after inversion crackdown, mixed data
Subscribe for More Information
09:01 EDTABTAbbott completes CFR Pharmaceuticals acquisition
Abbott has acquired control of CFR Pharmaceuticals, doubling its Latin American branded generics pharmaceutical presence and further expanding the company's presence in fast-growing markets. Through purchase of the controlling interest and tender offers described below, Abbott indirectly acquired more than 99% of CFR's ordinary shares for approximately $2.9B. The CFR acquisition immediately establishes Abbott among the top 10 pharmaceutical companies in Latin America, a market that is expected to reach $124B by 2018, with estimated annual growth rates of two to three times that of developed markets over the coming years, according to IMS. This transaction will not impact Abbott's ongoing earnings-per-share guidance for 2014. Abbott anticipates this transaction to be accretive to ongoing earnings per share in 2015 and increasing thereafter, before one-time transaction-related items which will be provided at a later date.
September 25, 2014
16:08 EDTACTActavis confirms generic Butrans patent challenge
Actavis confirmed that it has filed an Abbreviated New Drug Application, or ANDA, with the FDA seeking approval to market Buprenorphine Transdermal System, 5 mcg/hr, 10 mcg/hr and 20 mcg/hr. Actavis' ANDA product is a generic version of Purdue Pharma's Butrans, which is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate. Purdue Pharma L.P. filed suit against Actavis on September 24 in the U.S. District Court for the District of Delaware seeking to prevent Actavis from commercializing its ANDA product prior to the expiration of certain U.S. Patents. The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Actavis' ANDA for up to 30 months from the date the plaintiffs received notice of Actavis' ANDA filing or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities. Based on available information, Actavis believes it may be a "first applicant" to file an ANDA for the generic version of Butrans and, should its ANDA be approved, may be entitled to 180 days of generic market exclusivity.
08:51 EDTCOVMedtronic deal for Covidien still attractive despite new rules, says Bernstein
Bernstein believes that Medtronic's (MDT) deal to acquire Covidien (COV) is still attractive despite the new Treasury rules on tax inversions and the firm thinks the acquisition will still be completed. The firm estimates the transaction would still be 4% cash accretive in FY16 and 9% accretive in FY17 if Medtronic raises debt to fully finance the cash portion of the deal. Bernstein maintains its Outperform rating on Medtronic.
08:34 EDTACTValeant strength not solely due to Q3 update, says UBS
UBS said it does not believe Valeant's (VRX) 7% advance yesterday was solely attributable to the company's Q3 update, but that news reports that Actavis (ACT) may be competing with Allergan (AGN) to buy Salix (SLXP) may have led some investors to see Allergan as more vulnerable to Valeant. UBS won't rule out Allergan having alternative options, but the firm also believes Valeant has additional M&A ideas if a deal with Allergan does not work out. UBS maintains its Buy rating and $155 price target on Valeant.
September 24, 2014
09:11 EDTACTSalix up after CNBC reports merger talks with Actavis
Subscribe for More Information
09:11 EDTCOVSummer Street Director of Research to hold an analyst/industry conference call
Subscribe for More Information
09:03 EDTABTAbbott's U.S. tender offer for Chile's CFR Pharmaceuticals expired
Abbott announced the expiration of the tender offer for the purchase from U.S. holders of the ordinary shares of CFR Pharmaceuticals S.A., a Chilean corporation, and for the purchase from all holders, wherever resident, of CFR's outstanding ADS. The offer expired at 5 p.m., NYC time, on Sept. 23, and was not extended. A Chilean tender offer for CFR ordinary shares, which was made concurrently with the U.S. offer, expired at 5:30 p.m., Chilean time, on Sept. 23, and was not extended. The results of the U.S. offer will be announced on Sept. 26, at the time the results of the Chilean tender offer for CFR ordinary shares are announced.
09:02 EDTACTActavis, Salix in early merger talks, CNBC's Faber reports
Subscribe for More Information
06:23 EDTABT, COVExperts see new tax rules not halting inversions, WSJ reports
Subscribe for More Information
06:14 EDTACTPfizer, Actavis takeover talks ended last week, WSJ reports
Subscribe for More Information
September 23, 2014
16:20 EDTCOVOn The Fly: Closing Wrap
Stocks on Wall Street were lower after the U.S. took new action to clamp down on tax inversion deals and led airstrikes against Islamic State militants in Syria, while Europe reported weaker than expected manufacturing data. ECONOMIC EVENTS: In the U.S., the FHFA's home price index rose 0.1% in July to 212.7, missing expectations for an increase of 0.5%. Markit's preliminary manufacturing Purchasing Managers' Index for September came in at 57.9, slightly below the consensus forecast for a 58.0 reading. In China, HSBC's flash manufacturing PMI rose to 50.5 from a final reading of 50.2 in August, better than expectations. In Europe, Markit's composite flash PMI for the eurozone dipped to a nine-month low of 52.3, missing expectations for it to hold steady with its 52.5 reading for August. COMPANY NEWS: The shares of a number of companies that have announced or been speculated as targets in tax inversion deals fell after the U.S. Treasury last night issued new regulations that will make such deals less attractive. AstraZeneca (AZN), which has previously turned down an offer to be acquired by the U.S.'s Pfizer (PFE), sank $3.54, or 4.74%, to $71.13 despite a Bloomberg report that said Pfizer is still considering pursuing a deal with the U.K. drugmaker. AbbVie (ABBV), which has a deal in progress to acquire Shire (SHPG) and thus move its tax domicile to Ireland, fell $1.15, or 1.96%, to $57.56, while Shire shares slid $5.56, or 2.17%, to $250.74. Medtronic (MDT), which is pursuing its own inversion deal with Covidien (COV), dropped $1.90, or 2.88%, to $64.08. MAJOR MOVERS: Among the notable gainers was Herbalife (HLF), which rose $3.88, or 9.65%, to $44.09, bouncing back from a pullback yesterday that had been attributed to rumors of Carl Icahn selling out of his stake in the company. Also higher was Plug Power (PLUG), which rose 40c, or 9.57%, to $4.58 after the company's CEO gave FY15 revenue guidance that was above the consensus Street view in an interview with the Albany Business Review. Among the noteworthy losers was Ascena Retail (ASNA), which dropped $2.78, or 16.82%, to $13.75 after the apparel retailer's fourth quarter results and fiscal 2015 profit outlook trailed analysts' consensus estimates. Also lower were shares of used car retailer CarMax (KMX), which fell $5.01, or 9.49%, to $47.80 after the company reported sluggish comparable used car sales in its second quarter. INDEXES: The Dow declined 116.81, or 0.68%, to 17,055.87, the Nasdaq dropped 19.00, or 0.42%, to 4,508.69, and the S&P 500 fell 11.52, or 0.58%, to 1,982.77.
14:38 EDTACTActavis calls active on report Pfizer approached on takeover
Subscribe for More Information
14:23 EDTACTPfizer approached Actavis about takeover, Bloomberg reports
Pfizer (PFE) approached Actavis (ACT) to express interest in an acquisition, Bloomberg reports, citing people with knowledge of the matter said. No formal talks are ongoing and Pfizer has not made an offer, Bloomberg adds. Pfizer is still considering pursuing a deal with AstraZeneca (AZN) as well as other options, the report says. Shares of Actavis rallied 3% to $243.06 following the story. Reference Link
14:22 EDTACTActavis spikes on report Pfizer approached on takeover
Subscribe for More Information
14:12 EDTACTPfizer weighing options including AstraZeneca bid, Bloomberg says
Subscribe for More Information
14:12 EDTACTPfizer approached Actavis about takeover, Bloomberg reports
12:28 EDTACTSalix climbs after reports say Allergan discussing takeover
Subscribe for More Information
12:11 EDTCOVOn The Fly: Midday Wrap
Stocks on Wall Street were mixed and little changed at midday, amid new rules from the Obama administration on tax inversions and manufacturing data from around the globe. ECONOMIC EVENTS: In the U.S., the FHFA's home price index rose 0.1% in July to 212.7, missing expectations for a rise of 0.5%. Markit's preliminary manufacturing Purchasing Managers' Index for September came in at 57.9, slightly below the consensus forecast for a 58.0 reading. The Richmond Fed manufacturing index for September rose to 14, beating expectations for it to have dropped two points to 10. In China, HSBC's flash manufacturing Purchasing Managers' Index rose to 50.5 from a final reading of 50.2 in August, better than expectations. In Europe, Markit's composite flash PMI for the eurozone dipped to a nine-month low of 52.3, missing expectations for it to hold steady at the 52.5 seen in August. COMPANY NEWS: Shares of several companies, including a number in the pharmaceutical industry, are lower in early trading after the Treasury Department announced new regulations yesterday night that aim to make it tougher for U.S. companies to lower their tax burdens via mergers with foreign companies, otherwise known as "inversions." Among the stocks that moved lower after the new rules were announced was Astrazeneca (AZN), which had previously been a target of Pfizer (PFE) and fell about 4% near midday. Also lower were shares of both Shire (SHPG), which fell 2%, and Abbvie (ABBV), which dropped 1.6%, as the two have previously agreed to merge in a tax inversion deal. Medtronic (MDT) and Covidien (COV), which similarly agreed to an inversion merger, were down 3.3% and 2.7%, respectively. MAJOR MOVERS: Among the notable gainers was Salix Pharmaceuticals (SLXP), which rose more than 5% after The Wall Street Journal reported that Allergan (AGN) is in advanced talks on a deal to buy the company. Shares of Allergan were also up nearly 3% near midday, as the Journal also reported that Allergan rejected a recent buyout offer from Actavis (ACT). Among the noteworthy losers was Ascena Retail (ASNA), which dropped 16% after the apparel retailer's fourth quarter results and fiscal 2015 profit outlook trailed analysts' consensus estimates. Also lower following its own earnings report was auto retailer CarMax (KMX), which fell over 9%. INDEXES: Near midday, the Dow was down 32.91, or 0.19%, to 17,139.77, the Nasdaq was up 2.90, or 0.06%, to 4,530.59, and the S&P 500 was down 2.29, or 0.11%, to 1,992.00.
10:54 EDTENDP, ABT, COVStocks, analysts react to Treasury inversion crackdown
Subscribe for More Information
09:13 EDTACT, COV, ABTOn The Fly: Pre-market Movers
Subscribe for More Information
08:53 EDTABT, COVInversion regulations look more onerous than expected, says FBR Capital
FBR Capital says the new regulations announced last night by the Treasury and IRS contain appear more onerous than expected. FBR points out the proposed changes remove the ability of inverting companies to make "hopscotch loans" between the foreign and domestic subsidiaries. The firm believes the regulations will not end the practice of inversions, and it still expects completion of already announced deals.
08:31 EDTACTSalix takeout price could be $200 per share, says Leerink
Leerink estimates a takeout valuation for Salix (SLXP) of $200 per share, but says it would start recommending investors take profits above $185. The firm believes a potential deal with Allergan (AGN) would likely include an above-average break-up fee. Leerink thinks a competitive bid could surface, and points out Actavis (ACT) has more overlapping cost structure with Salix than Allergan. Shares of Salix are up 9% to $173.48 in pre-market trading after Wall Street Journal reported the company is in merger talks with Allergan.
08:00 EDTENDPAuxilium rejection of first Endo offer not surprising, says UBS
Subscribe for More Information
07:05 EDTCOVMedtronic will still pursue Covidien deal, says Citigroup
Subscribe for More Information
07:02 EDTENDPAuxilium now more likely to be acquired, says RBC Capital
After the U.S. Treasury announced a crackdown on tax inversion deals, RBC Capital thinks that, as a result, Auxilium's (AUXL) proposed takeover of QLT will not occur. The firm believes that instead Auxilium will be acquired by already inverted Endo (ENDP) or another pharmaceutical company. The firm expects Endo to raise its bid for Auxilium to $30-$35, and it keeps an Outperform rating on Auxilium.
06:40 EDTACTPiper says don't dismiss potential Pfizer bid for Actavis
Piper Jaffray says it would not be dismissive of Pfizer (PFE) as a potential acquirer of Actavis (ACT). Piper believes Pfizer's public M&A comments are supportive of Actavis' exposure to complex generics and emerging markets. The firm views Actavis shares as attractively valued, irrespective of the acquisition chatter. It reiterates an Overweight rating on the stock with a $280 price target.
06:28 EDTABTTreasury rules may put Mylan deal at risk, says BMO Capital
BMO Capital believes Treasury's new inversion rules may put the tax benefits of Mylan's (MYL) planned acquisition of Abbott's (ABT) established products business at risk. BMO also thinks the rules impact Salix's (SLXP) pending deal for Cosmo Pharmaceuticals, which it feels may help make a deal with Allergan (AGN) more likely.
05:56 EDTCOV, ABTTreasury, IRS announce plans to reduce inversion tax benefits
Subscribe for More Information
September 22, 2014
20:01 EDTENDPEndo management to meet with Sterne Agee
Subscribe for More Information
19:03 EDTACTAllergan rejected buyout bid from Actavis, in advanced talks for Salix, WSJ says
Subscribe for More Information
10:15 EDTACTOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Actavis (ACT) downgraded to Equal Weight from Overweight at Barclays... Aetna (AET) downgraded to Neutral from Buy at BofA/Merrill... Auxilium (AUXL) downgraded to Hold from Buy at Stifel... CARBO Ceramics (CRR) downgraded to Neutral from Buy at Sterne Agee... Commerzbank (CRZBY) downgraded to Underperform from Neutral at Exane BNP Paribas... Concur (CNQR) downgraded to Neutral from Buy at Nomura... Dresser-Rand (DRC) downgraded to Neutral from Accumulate at Global Hunter... Finish Line (FINL) downgraded to Equal Weight from Overweight at Morgan Stanley... General Communications (GNCMA) downgraded to Hold from Buy at Drexel Hamilton... InvenSense (INVN) downgraded to Neutral from Outperform at RW Baird... Las Vegas Sands (LVS) downgraded to Market Perform from Outperform at Wells Fargo... Lindsay Corp. (LNN) downgraded at Sterne Agee... Melco Crown (MPEL) downgraded to Market Perform from Outperform at Wells Fargo... Outerwall (OUTR) downgraded to Sell from Neutral at B. Riley... PSEG (PEG) downgraded to Hold from Buy at Jefferies... Realogy (RLGY) downgraded to Underperform from Neutral at Credit Suisse... Regal-Beloit (RBC) downgraded to Accumulate from Buy at Global Hunter... SABMiller (SBMRY) downgraded to Market Perform from Outperform at Bernstein... Saba Software (SABA) downgraded to Neutral from Buy at B. Riley... Suburban Propane (SPH) downgraded to Market Perform from Outperform at Wells Fargo... Swiss Re (SSREY) downgraded to Underperform from Neutral at Exane BNP Paribas... Towers Watson (TW) downgraded to Buy from Conviction Buy at Goldman... Valmont (VMI) downgraded at Sterne Agee... Walgreen (WAG) downgraded to Equal Weight from Overweight at Barclays... Watts Water (WTS) downgraded to Neutral from Buy at Janney Capital... Wynn Resorts (WYNN) downgraded to Market Perform from Outperform at Wells Fargo... Yahoo (YHOO) downgraded to Neutral from Buy at BofA/Merrill.
09:40 EDTENDPEndo says continues to feel Auxilium transaction 'compelling'
Subscribe for More Information
08:10 EDTACTActavis multiple expansion case 'compelling,' says JPMorgan
Subscribe for More Information
07:11 EDTENDPQLT Inc. says, Auxilium determines Endo proposal not superior
Subscribe for More Information
07:10 EDTENDPQLT Inc. says, Auxilium determines Endo proposal not superior
07:06 EDTABTAbbott price target raised to $48 from $44 at RBC Capital
Subscribe for More Information
07:02 EDTENDPAuxilium board determines QLT Inc.'s agreement superior to Endo proposal
Auxilium (AUXL) announced that its board has reviewed the unsolicited, non-binding and conditional proposal from Endo (ENDP) and, after consulting with its independent financial and legal advisors, has unanimously determined it is not a superior proposal under the terms of its existing merger agreement with QLT Inc. (QLTI) and has unanimously reaffirmed its recommendation that Auxilium's stockholders vote in favor of the adoption of such merger agreement. In addition, the board has determined that Endo's proposal significantly undervalues Auxilium. However, under the terms of the merger agreement with QLT, Auxilium maintains the right to engage in discussions with Endo and other third parties, subject to certain conditions in the merger agreement. In unanimously reaffirming its recommendation that Auxilium's stockholders vote in favor of the adoption of the existing merger agreement with QLT, the board confirmed that it is not withdrawing, modifying, withholding, changing or qualifying its recommendation with respect to such merger agreement, or proposing to do so.
05:52 EDTACTActavis downgraded to Equal Weight from Overweight at Barclays
Subscribe for More Information
September 19, 2014
16:24 EDTENDPStocks rise after Fed keeps pledge for 'considerable time' before rate hike
Subscribe for More Information
14:18 EDTACTAkorn competition settlement over VersaPharm deal approved by FTC
Subscribe for More Information
11:25 EDTCOV, ABTSenators bring bill requiring companies to settle before inverting
U.S. Senators Sherrod Brown and Dick Durbin announced new legislation requiring corporations to "Pay What You Owe Before You Go" – settling their U.S. tax bill before relocating to a foreign country. "Everyone knows that before you leave a restaurant you have to settle your tab," Brown said. "Corporations shouldn’t get to play by different rules. While it is critical that we reach a long-term solution that reforms our international corporate tax code by implementing a global minimum tax and reducing the statutory tax rate, this bill is an immediate, commonsense measure to ensure businesses settle up before leaving the U.S." Among the deals or possible transactions that involve inversion are Mylan's (MYL) acquisition of Abbott (ABT), Medtronic's (MDT) acquisition of Covidien (COV) and Valeant's (VRX) proposed takeover of Allergan (AGN).
September 18, 2014
20:23 EDTENDPAuxilium downgraded to Neutral from Buy at Goldman
Goldman Sachs downgraded Auxilium (AUXL) to Neutral citing a balanced risk/reward following the post-Endo (ENDP) takeover bid rally. The firm raised its price target for shares to $31 from $28.
11:15 EDTENDPRepros sinks after panel backs tests for testosterone therapies
Subscribe for More Information
07:50 EDTENDPEndo Auxilium deal would be disappointing over longer term, says Cantor
Subscribe for More Information
06:10 EDTENDPFDA panel votes 20-1 to study changes to testosterone therapies
Subscribe for More Information
<< 1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use